Skip to main content

Media Category: Safety, Tolerability & Adherence

Generics and biosimilars in Multiple Sclerosis: understanding efficacy, safety and clinical confidence

Written by Diane Pitard on .

Generics and biosimilars are becoming increasingly relevant in Multiple Sclerosis (MS) care as more follow-on treatments enter clinical practice. In this keynote, Thomas Berger explains how generics and biosimilars differ, how they are evaluated and approved, and why regulatory quality, bioequivalence, immunogenicity and pharmacovigilance are central to confidence in their use. Key Insights from the Lecture: Generics and biosimilars are already established in other areas of neurology, but their use in Multiple Sclerosis remains relatively recent. A major concern among both...

Continue reading

Multiple Sclerosis and pregnancy: balancing treatment, safety and family planning

Written by ParadigMS Foundation on .

Pregnancy and family planning remain important considerations in the management of Multiple Sclerosis (MS), particularly as treatment options become more effective and diverse. In this expert session, Thomas Berger reviews how different disease-modifying therapies (DMTs) can influence decisions before, during and after pregnancy, and highlights the importance of evidence-based counselling, individualized treatment planning and careful consideration of breastfeeding. Key Insights from the Lecture: Pregnancy itself is not presented as the main risk for women with Multiple Sclerosis;...

Continue reading

Long-term Efficacy and Safety of Anti-CD20 Therapies

Written by ParadigMS Foundation on .

Anti-CD20 therapies have transformed the treatment landscape of Multiple Sclerosis (MS), offering highly effective disease control through targeted B-cell depletion. As these therapies are increasingly used early in the disease course and maintained over many years, understanding their long-term efficacy, safety, and optimal use has become essential for clinical practice. In this webinar, Celia Oreja-Guevara and Patrick Vermersch review the latest evidence on anti-CD20 therapies, including ocrelizumab, ofatumumab, rituximab, and ublituximab. Drawing from pivotal clinical trials, extension...

Continue reading

The clinical management of NMOSD

Written by ParadigMS Foundation on .

Neuromyelitis optica spectrum disorder (NMOSD) is a rare but severe relapsing disease of the central nervous system, characterized by attacks that lead to cumulative disability. Unlike multiple sclerosis, progression is not continuous but driven by relapses, making early diagnosis and rapid treatment essential. Advances in biomarkers, classification, and targeted therapies are reshaping how clinicians approach NMOSD management. Key Insights from the Lecture: NMOSD is a rare but globally variable disease Disability is driven by relapses, not progression Aquaporin-4 antibodies...

Continue reading

The Role of Microglia in Multiple Sclerosis: Implications for Treatment with Bruton’s Tyrosine Kinase Inhibitors

Written by ParadigMS Foundation on .

Microglia are increasingly recognised as central regulators of neuroinflammation in Multiple Sclerosis (MS). Beyond their traditional classification, advances in molecular biology have revealed a spectrum of functional states that influence both tissue damage and repair. This lecture provides a concise overview of microglial biology in MS and explores how emerging therapeutic strategies, particularly Bruton tyrosine kinase (BTK) inhibitors, may modulate these cells to impact disease progression. Key Insights from the Lecture: Microglia as central orchestrators of CNS immunity: Microglia...

Continue reading

Real-Life Experiences with biosimilars 

Written by ParadigMS Foundation on .

Key takeaways Generics and biosimilars are increasingly relevant in Multiple Sclerosis (MS) as healthcare systems seek cost containment without compromising clinical outcomes. Biosimilars are not identical copies, but are rigorously evaluated to demonstrate high similarity to reference biologics in structure, efficacy, safety, and immunogenicity through the EMA/FDA “totality of evidence” framework. Clinical trials and real-world evidence consistently show comparable efficacy and safety between originator biologics and biosimilars used in MS, including interferon beta, rituximab (off-label),...

Continue reading

  • 1
  • 2

FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.